Lavasanifar A - Search Results

1

Mitigation of Tacrolimus-Associated Nephrotoxicity by PLGA Nanoparticulate Delivery Following Multiple Dosing to Mice while Maintaining its Immunosuppressive Activity.

Alshamsan A, Binkhathlan Z, Kalam MA, Qamar W, Kfouri H, Alghonaim M, Lavasanifar A. Alshamsan A, et al. Among authors: lavasanifar a. Sci Rep. 2020 Apr 21;10(1):6675. doi: 10.1038/s41598-020-63767-1. Sci Rep. 2020. PMID: 32317681 Free PMC article.

2

Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells.

Haddadi A, Elamanchili P, Lavasanifar A, Das S, Shapiro J, Samuel J. Haddadi A, et al. Among authors: lavasanifar a. J Biomed Mater Res A. 2008 Mar 15;84(4):885-98. doi: 10.1002/jbm.a.31373. J Biomed Mater Res A. 2008. PMID: 17647224

3

Polymeric micelles for the solubilization and delivery of STAT3 inhibitor cucurbitacins in solid tumors.

Molavi O, Ma Z, Mahmud A, Alshamsan A, Samuel J, Lai R, Kwon GS, Lavasanifar A. Molavi O, et al. Among authors: lavasanifar a. Int J Pharm. 2008 Jan 22;347(1-2):118-27. doi: 10.1016/j.ijpharm.2007.06.032. Epub 2007 Jun 26. Int J Pharm. 2008. PMID: 17681440 Free PMC article.

4

Polymeric micellar delivery reduces kidney distribution and nephrotoxic effects of Cyclosporine A after multiple dosing.

Aliabadi HM, Elhasi S, Brocks DR, Lavasanifar A. Aliabadi HM, et al. Among authors: lavasanifar a. J Pharm Sci. 2008 May;97(5):1916-26. doi: 10.1002/jps.21036. J Pharm Sci. 2008. PMID: 17786948

5

Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma.

Binkhathlan Z, Somayaji V, Brocks DR, Lavasanifar A. Binkhathlan Z, et al. Among authors: lavasanifar a. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jun 15;869(1-2):31-7. doi: 10.1016/j.jchromb.2008.05.003. Epub 2008 May 10. J Chromatogr B Analyt Technol Biomed Life Sci. 2008. PMID: 18514043

6

Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity.

Hamdy S, Molavi O, Ma Z, Haddadi A, Alshamsan A, Gobti Z, Elhasi S, Samuel J, Lavasanifar A. Hamdy S, et al. Among authors: lavasanifar a. Vaccine. 2008 Sep 15;26(39):5046-57. doi: 10.1016/j.vaccine.2008.07.035. Epub 2008 Aug 3. Vaccine. 2008. PMID: 18680779

7

Immunomodulatory and anticancer effects of intra-tumoral co-delivery of synthetic lipid A adjuvant and STAT3 inhibitor, JSI-124.

Molavi O, Ma Z, Hamdy S, Lavasanifar A, Samuel J. Molavi O, et al. Among authors: lavasanifar a. Immunopharmacol Immunotoxicol. 2009 Jun;31(2):214-21. doi: 10.1080/08923970802380452. Immunopharmacol Immunotoxicol. 2009. PMID: 18798092

8

Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine.

Alshamsan A, Haddadi A, Incani V, Samuel J, Lavasanifar A, Uludağ H. Alshamsan A, et al. Among authors: lavasanifar a. Mol Pharm. 2009 Jan-Feb;6(1):121-33. doi: 10.1021/mp8000815. Mol Pharm. 2009. PMID: 19053537

9

Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat.

Binkhathlan Z, Hamdy DA, Brocks DR, Lavasanifar A. Binkhathlan Z, et al. Among authors: lavasanifar a. Xenobiotica. 2010 Jan;40(1):55-61. doi: 10.3109/00498250903331056. Xenobiotica. 2010. PMID: 19903013

10

The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine.

Alshamsan A, Hamdy S, Samuel J, El-Kadi AO, Lavasanifar A, Uludağ H. Alshamsan A, et al. Among authors: lavasanifar a. Biomaterials. 2010 Feb;31(6):1420-8. doi: 10.1016/j.biomaterials.2009.11.003. Epub 2009 Nov 13. Biomaterials. 2010. PMID: 19913908

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters